Notice of Results

RNS Number : 7889Z

Genedrive PLC

15 January 2020

 

genedrive plc

("genedrive" or the "Company")

Notice of Results

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2019 on Tuesday, 4 February 2020.

For further details please contact:

genedrive plc		www.genedriveplc.com
David Budd: CEO / Matthew Fowler: CFO		[phone]
Peel Hunt LLP		[phone]
James Steel / Oliver Jackson
Stanford Capital Partners Limited		[phone]
Patrick Claridge / John Howes
Walbrook PR Ltd (Media Relations & Investor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy		[phone] / [phone]

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).

Further details can be found at: www.genedriveplc.com and www.genedrive.com.

 

END

 

 

NORBIMATMTTBBMM